Protocol

“Smartphone Medication Adherence Saves Kidneys” for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial

John McGillicuddy¹, MD; Jessica Chandler², PhD; Luke Sox², BSc; Martina Mueller², PhD; Lynne Nemeth², PhD; Prabhakar Baliga¹, MD; Frank Treiber², PhD

¹College of Medicine, Medical University of South Carolina, Charleston, SC, United States
²College of Nursing, Medical University of South Carolina, Charleston, SC, United States

Corresponding Author:
Jessica Chandler, PhD
College of Nursing
Medical University of South Carolina
99 Jonathan Lucas Street
Charleston, SC,
United States
Phone: 1 843 792 1928
Email: chandlje@musc.edu

Abstract

Background: Kidney transplant recipients’ poor medication adherence and poor control of comorbidities, particularly hypertension, are risk factors for graft rejection, graft loss, and death. Few randomized controlled trials (RCTs) have been successful in improving sustained medication adherence and blood pressure control among kidney transplantation recipients. We provide rationale for an RCT evaluating a mobile health medical self-management system for kidney transplantation recipients called Smartphone Medication Adherence Saves Kidneys (SMASK).

Objective: Our objective is to determine whether SMASK is efficacious in improving medication adherence and sustaining blood pressure control among kidney transplantation recipients with uncontrolled hypertension and poor medication adherence compared to an enhanced standard care.

Methods: This two-arm, 6-month, phase II single-site efficacy RCT will involve 80 kidney transplantation recipients. Participants will be randomly assigned to the SMASK intervention arm or control arm. SMASK includes multilevel components: automated reminders from an electronic medication tray; tailored text messages and motivational feedback, guided by the self-determination theory; and automated summary reports for providers. Evaluations will be conducted preintervention, at 3 and 6 months, and posttrial at 12 months. Specific aims are to test the hypotheses that compared to standard care, the SMASK cohort will demonstrate significantly improved changes at 3, 6, and 12 months in the primary outcome variables medication adherence (proportion with electronic monitor-derived score >0.90) and blood pressure control (proportion meeting and sustaining adherence to the Kidney Disease Improving Global Outcomes [KDIGO] guidelines for blood pressure control); the secondary outcome variables provider adherence to KDIGO guidelines, measured by timing of medication changes and changes in self-determination theory constructs; and the exploratory outcome variables estimated glomerular filtration rate, variability in calcineurin inhibitor trough levels, and proportion of patients meeting and sustaining the 24-hour ambulatory blood pressure below 130/80 mm Hg. After the 6-month evaluation, interviews with a random sample of SMASK subjects (n=20) and health care providers (n=3-5) will assess user reactions including acceptability, usability, and aids/barriers to sustainability. Data from the RCT and interviews will be triangulated to further refine and optimize SMASK and prepare for a multisite effectiveness RCT.

Results: The SMASK project received funding from National Institute of Diabetes and Digestive and Kidney Diseases in June 2016, obtained institutional review board approval in April 2016, and began data collection in July 2016. As of July 2018, we completed enrollment with a total of 80 participants.

Conclusions: This study will provide data regarding the efficacy of SMASK to improve medication adherence and blood pressure control in a cohort of hypertensive kidney transplant recipients. An efficacious SMASK intervention will pave the way...
for a larger, multicenter, effectiveness RCT powered sufficiently to evaluate clinical events in a real-world setting and with the potential to demonstrate improved outcomes at lower cost than standard care.

**International Registered Report Identifier (iRRID):** DERR1-10.2196/13351

**(JMIR Res Protoc 2019;8(6):e13351)** doi: 10.2196/13351

**KEYWORDS**
mHealth; kidney transplant; medication adherence; digital health

**Introduction**

End-stage renal disease (ESRD) affects more than 700,000 people living in the United States; of these, approximately 95,000 are currently awaiting kidney transplantation [1,2]. Kidney transplantation is the treatment of choice for eligible patients with ESRD, as it offers superior quality of life, improved life expectancy, and better psychosocial functioning, all at a lower cost than maintenance hemodialysis [3-6].

Advances in the medical and surgical care of transplant recipients have not resulted in optimal long-term graft survival. The current 5-year graft survival rate is only 78% [2], and the average graft half-life is only ~9 years [7]. Poor medication adherence and poor control of comorbid medical conditions, particularly hypertension, are major drivers of suboptimal transplantation outcomes [8-13]. Nonadherence to prescribed medical regimens has been identified as a primary risk factor for graft rejection, graft loss, and death [14-18]. Even small degrees of nonadherence to immunosuppressant medications confer a significantly increased risk of graft rejection or graft loss [16,18]. In a meta-analysis published in 2007, approximately 35% of American kidney transplantation recipients demonstrated nonadherence to medications posttransplantion [19], with other more recent studies reporting values of 20%-40% [20-22].

Although medication adherence is critical for optimal kidney transplantation outcomes, until relatively recently, there was a paucity of research examining interventions directed at improving adherence. Our formative research has shown that kidney transplantation recipients have a high rate of smart mobile phone ownership, are comfortable being monitored using mobile health (mHealth) technology, and have an overall positive attitude toward mHealth [23,24]. We previously conducted a small, 3-month, two-arm randomized controlled trial with 20 kidney transplant recipients that involved a patient-centered, behavioral theory-guided mHealth intervention (Smartphone Medication Adherence Saves Kidneys [SMASK]). SMASK included tailored motivational/social reinforcement short message service (SMS) messages, an electronic medication tray with cellular connectivity and reminder alerts, and Bluetooth-enabled blood pressure (BP) self-monitoring, designed to improve both medication adherence and BP control [25]. The recruitment process included confirmation of poor medication adherence using an electronic medication tray (<80% over 1-month monitoring) and documented uncontrolled hypertension prior to and following the 1-month screening process. The SMASK group demonstrated significantly greater improvements in electronically calculated medication adherence (average of 0.92 vs 0.56, P<.50) and guideline-based systolic BP (SBP) control (90% vs 10%, P<.50) across the 3-month trial compared to the standard care (SC) control group. A recent 12-month posthoc follow-up of the subjects’ clinic SBPs demonstrated persistence of the SBP difference between the groups (132 mm Hg vs 154 mm Hg), suggesting that the improvement in medication adherence was sustained in the intervention group [26].

Investigation on this topic has dramatically increased. A 2017 review of medication adherence intervention trials performed in solid organ transplant recipients identified 21 randomized controlled trials (RCTs), with 15 involving kidney transplant recipients. Two of the studies identified were our 3-month RCT [25] and the subsequent 12-month post trial follow-up study [27]. Intervention approaches in kidney transplant recipient studies varied widely and included cognitive behavioral therapy aimed at improving medication adherence [28,29]; psychoeducation [30]; intensified pharmaceutical care [31]; financial assistance programs [32]; electronic monitoring and reminders [33-35]; and our mHealth system that provides reminders, tracks medication taking, and delivers tailored motivational/social reinforcement messages based on the level of adherence.

Although approximately half of these RCTs involving kidney transplant recipients demonstrated a significant improvement in medication adherence, and the methodologies and measures of adherence varied widely. Most either did not examine drug blood levels or could not demonstrate an improvement in the examined levels related to medications(s) taken. None of the five RCTs in kidney transplant recipients that examined transplant outcomes (ie, estimated glomerular filtration rate [eGFR], graft rejection, graft survival, and serum creatinine) demonstrated significant improvement. None of these RCTs lasted >12 months, and the incidence rates of rejection and other relevant parameters were too infrequent to allow comparisons. Importantly, although poorly controlled hypertension is highly prevalent (70%-93%) [8,10,11] and a leading contributor to posttransplant reductions in kidney function, changes in associated physiological function (eg, BP) were not measured in any RCT except ours [26].

The authors concluded that research on medication adherence programs in the transplant population is misguided in that it often does not include patients verified as having poor medication adherence, lacks the use of programs that are engaging and foster sustained regimen adherence, and does not evaluate clinically relevant transplant-specific outcomes. Our work has addressed several of these issues including identification and recruitment of kidney transplant recipients with verified poor medication adherence using multiple indices.

http://www.researchprotocols.org/2019/6/e13351/
We chose to employ a two-part screening process including BP measurement and one-time medication adherence via medication possession ratio screening followed by a 1-month screening to determine medication nonadherence via a Bluetooth-enabled electronic pill box with audio and visual alerts disabled. In a pilot study, we found that 70% of otherwise eligible kidney transplant recipients were medication nonadherent [25], and thus far, we have identified a higher (~82%) proportion of such recipients in this RCT. Although medication nonadherence is on a continuum, it has been well demonstrated that even small degrees of medication nonadherence have negative effects on kidney transplant recipient outcomes [16-18]. We have employed a patient-centered, theory-guided, iterative design process to develop a medical regimen self-management program aimed at fostering self-efficacy and autonomous motivation to help ensure regimen adherence is sustained. In light of the expense and length of follow-up necessary to demonstrate significant clinical outcome improvements (eg, reduced acute rejection, graft loss, and death), we have adopted a strategy to investigate surrogate markers that are shown to be strongly predictive of worsened long-term outcomes (ie, BP and percent coefficient of variation [%cv]) [36-44]. A recent review of the literature on hypertension management in kidney transplant recipients concluded that posttransplant hypertension is prevalent (70%-90%), multifactorial, and rarely controlled (~33%) [8]. Specifically, among kidney transplant recipients at our transplant center, we found the prevalence of hypertension to be 95%, with only 34% having met the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for hypertension control at a mean follow-up of 7.3 (SD 4.5) years after transplant [45]. Uncontrolled hypertension remains a significant problem in kidney transplant recipients; thus, efficacious intervention programs are warranted.

This paper describes a 6-month efficacy RCT with a 6-month posttrial follow-up, utilizing a further refined SMASK mHealth system in kidney transplant recipients verified to be medication nonadherent with poorly controlled hypertension. The aims of this study are twofold: (1) to assess the efficacy of our mHealth system for monitoring and enhancing medication adherence and BP control during the 6-month active trial and the 6-month post-trial follow-up period and (2) to evaluate provider adherence to BP management guidelines and changes in participants’ levels of self-efficacy and autonomous motivation to sustain engagement in the medical regimen over time. Exploratory outcome variables will include changes in eGFR and variability of calcineurin inhibitor (CNI) trough levels (%cv).

**Methods**

**Trial Design**

This is a two-arm, phase II efficacy RCT involving 80 kidney transplant recipients with poor medication adherence and uncontrolled hypertension, with subjects as the unit of randomization (ClinicalTrials.gov: NCT02827695). Each of the subjects was recruited and randomly assigned to the intervention or control arm by a statistician (who is not involved in subject recruitment or data collection) using a computer-generated random sequence. A flow chart of the study design is presented in Figure 1.
Study Setting
This study is conducted at the Medical University of South Carolina (MUSC) in the Kidney Transplant Clinic. MUSC is a tertiary referral academic center in Charleston, SC, and the only transplant center in the state.

Study Participants
The participants are adult kidney transplant recipients with uncontrolled hypertension who have met the inclusion/exclusion criteria. Potentially eligible study patients were identified through weekly data extractions from the appointment database.

The inclusion criteria for participants were age >18 years (male or female), first- or second-time recipient of a functioning solitary kidney transplantation performed 6 weeks to 60 months earlier, legally competent, assent provided by the transplant physician so that the patient is able to participate, patient prescribed ≥3 medications for immunosuppression and hypertension, electronic pill tray–based medication adherence score <0.85 across a 1-month screening period, uncontrolled systolic hypertension (SBP ≥130 mm Hg) at the screening visit and baseline evaluation (following 1-month medication monitoring period), and 24-hour ambulatory SBP ≥130 mm Hg following the medication monitoring period.

The exclusion criteria were severe cognitive impairment/dementia; inability to self-administer medications, self-measure BP, or use a mobile phone; poor cellular coverage at home; inability to speak, hear, or understand English; history of psychiatric illness or substance abuse; planned pregnancy; and vulnerable populations such as pregnant or nursing women, prisoners, and institutionalized individuals.
Prototype of the Mobile Health Smartphone Medication Adherence Saves Kidneys System

The SMASK mHealth system characterized in Figure 2 consists of a wireless global system for mobile communication electronic medication tray (Vaica, Tel Aviv, Israel), a wireless validated Bluetooth low energy–enabled BP monitor (UA-767 Plus BT device [46]), and a smartphone (Android running Lollipop or newer operating system or iPhone 4 or newer). The medication tray plugs into an ordinary 110 V outlet, has 28 compartments (up to 4 doses per day for 7 days), time stamps compartment use, and is capable of providing reminder signals. At the prescribed dosing day and time, a blinking blue light is activated. If, after 30 minutes, the compartment lid has not been opened and closed, a loud intermittent chime automatically activates for 30 minutes. If, at the end of those 30 minutes, the compartment lid still has not been opened, an automated reminder phone call or SMS is delivered to the subject’s mobile phone. Microelectronic circuitry in each compartment on the tray date and time stamps the opening of the compartment lid. These signals are relayed via an internal modem to the Viaca server for processing. Data will then be sent directly to a HIPAA (Health Insurance Portability and Accountability Act of 1996)-compliant relational database housed at MUSC. Personalized motivational and positive reinforcement SMS messages will be automatically delivered initially based on the previous day’s calculated medication adherence. After 2 consecutive weeks of a calculated adherence score of 1.0, message delivery will be tapered from daily to several times per week on a 3-day average variable interval schedule. The schedule will revert to daily delivery when and if a subject’s calculated weekly adherence score is <0.9. The library of motivational/social reinforcement SMS messages was developed by enhancing the library of messages used in the earlier mHealth medication adherence studies [25,26]. This step was guided by underlying tenants of competency (akin to self-efficacy) and autonomous motivation from the self-determination theory [47,48], tailored to the subject based on their responses to a questionnaire designed to identify underlying motivating themes for consistently engaging in the medical regimen.

Participants will be sent SMS messages every 3 days as a reminder to measure their BP with the Bluetooth-enabled A&D UA-767 Plus BP monitor (A&D Medical, San Jose, CA). They will be instructed to measure their BP in the morning and evening every third day by using our resting BP protocol (described under Clinic Resting Blood Pressure). They will also receive a tailored positive reinforcement SMS message the day after successful completion of their BP measurements. An app will be installed on their smartphone, which will securely receive and transmit the BP data to the MUSC-housed server. The app will also provide text instructions throughout the BP protocol and a video clip module demonstrating use of the app and the BP monitor.

A weekly SMASK dashboard summary report, tailored to the treating physician’s preferences, will be delivered via email (Figure 3). The report will summarize each subject’s medication adherence and adherence to the BP self-monitoring schedule for the prior 2 weeks. Color coding will be used to indicate where the subject lies relative to the desired goals (ie, SBP <130 mm Hg and adherence score >0.90). In addition, a breakdown of the BP readings obtained over the 2 weeks will be provided with systolic and diastolic pressures. The treating physician will make adjustments to the medical regimen, as indicated and guided by the KDIGO guidelines [49]. The physician will notify the study coordinator of the changes via email. Any medication changes made by the treating physician will be mirrored in the programming of the medication tray after the study coordinator confirms with the patient that the changes have been enacted. The research manager and staff will be contacted via email, and the SMASK participants will be contacted via their preferred mode (SMS, email, or phone) when they fail to measure BP or when the measured BP is outside of the threshold ranges established by the treating physician, or they will be contacted via an SMS text when the SimpleMed+ tray identifies lack of medication adherence.
Figure 2. “Smartphone Medication Adherence Saves Kidneys” schematic.

Figure 3. Example of a “Smartphone Medication Adherence Saves Kidneys” participant’s weekly summary report to the provider. AVG RDG: average reading, SBP: systolic blood pressure; BP: blood pressure; MRN: medical record number.
Calculation of Adherence Score

A detailed description of the medication adherence score calculation by Russell et al is available elsewhere [50]. We will employ a modification of the algorithm to allow for dosing schedules other than the twice daily schedule. Our subjects will be instructed that to be considered fully adherent, their medications have to be taken within a 3-hour window of the prescribed dosing time. A dose taken within the 3-hour window will be assigned a full score for that dosing time, a dose taken outside the 3-hour window but within a 6-hour window will be assigned a half score for that dosing time, and a missed dose will be assigned a score of 0. Each subject will be assigned a score from 0.0 to 1.0 for each day. The scores for each subject will be averaged over each week.

Identification of Medication Nonadherent Patients with Uncontrolled Hypertension

Patients who meet the initial eligibility criteria, including a resting BP evaluation (SBP ≥ 130 mm Hg), and provide informed consent will be enrolled in a 30-day screening period using the SimpleMed+ with its reminder functions disabled. Subjects will be given a demonstration of how to properly use the medication tray and will be required to demonstrate successful use of the tray before completion of the visit. They will receive written and oral instructions explaining that to be considered fully adherent, they must take their medications within 90 minutes of the prescribed dosing time. After confirming successful connection with the server, the tray will be programmed by the study manager to accurately reflect the subjects’ medication dosing schedule. At the conclusion of the 1-month screening period, our modification [25] of the adherence equation by Russell et al will be used to calculate a medication adherence score for each subject. Only subjects with a cumulative adherence score <0.85 across the 1-month screening period will be eligible for randomization to either the mHealth intervention group or the attention control SC group.

Attention Control Standard Care Group

The enhanced attention control SC group will receive SC at the MUSC Kidney Transplant clinic. SC includes clinic visits as deemed appropriate, education on all matters related to posttransplantation medical care, and 24-hour phone availability of transplant coordinators. Participants randomized to the SC group will continue to use their SimpleMed+ medication tray, with its reminder functions still disabled, for an additional 6 months. To control for attention exposure, the subjects in the SC group will receive SMS messages on health-related topics excluding medication adherence. These messages include healthy lifestyle tips related to physical activity, dietary intake, nonexposure to first- or second-hand smoke, and limited alcohol intake. The SMS messages will be delivered every 3 days to approximate the schedule of the mHealth intervention group. SMS messages will include links to video or PDF content that require 3-5 minutes to review.

Mobile Health Intervention

The participants randomized to the intervention arm will receive the SMASK mHealth system, described in detail above, for the 6-month active trial. Subjects will be provided and instructed on use of the previously validated A&D BP device, and the SMASK app will be installed on their smartphone. The escalating reminder functions of the SimpleMed+ will be enabled. The SMASK subjects will again receive written and oral instructions on adherence criteria (ie, all medications are to be taken within a 180-min window centered on the dosing time; BP is to be measured every 3 days).

SMASK subjects will complete a questionnaire on beliefs, values, and life goals with the responses used in a tree-structured algorithm to generate tailored motivational and positive reinforcement messages that are delivered to promote self-efficacy for medication adherence and autonomous regulation for sustained behavior change.

A technical support phone number will be provided in several forms (paper copy, refrigerator magnet, and SMASK app) for assistance. At the conclusion of the study, subjects will return the SimpleMed+, A&D BP monitor, and smartphone (if one was borrowed) and complete a brief questionnaire assessing their opinions of the mHealth system.

Active Trial Evaluations and Follow-Up Phase

All subjects will be followed up for an additional 6 months following the 6-month active trial. Patients will continue to attend the clinic at a frequency determined by the provider. At 1, 3, 6, and 12 months after randomization into the SMASK or SC group, subjects will be assessed on medication adherence using medication possession ratio checks, clinic resting BPs, and completion of a brief set of questionnaires including measures to assess self-determination theory tenants of autonomous self-regulation and self-efficacy (Table 1). Providers are assessed on adherence to BP management protocols and goals. The timeliness and appropriateness of medication changes will be evaluated according to KDIGO guidelines across both groups at the conclusion of the study.
## Table 1. List of measures and evaluation time points.

| Outcome variables                  | Measurements/instruments used                                      | Screening | Baseline | 1 month | 3 months | 6 months | 12 months |
|------------------------------------|--------------------------------------------------------------------|-----------|----------|---------|----------|----------|-----------|
| **Primary outcomes**               |                                                                    |           |          |         |          |          |           |
| Medication adherence               | Vaica (time-stamped)                                               | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| BP<sup>a</sup>                     | Clinic resting SBP<sup>b</sup>                                      | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| **Secondary outcomes**             |                                                                    |           |          |         |          |          |           |
| Therapeutic Inertia                | Provider adherence to KDIGO<sup>c</sup> goals: Temporal medication changes (date of medication change following medication adherence) and BP feedback (biweekly SMASK<sup>d</sup> reports for SMASK participants) and from clinic visits for all subjects (Figure 2) | Weekly<sup>e</sup> | Weekly<sup>e</sup> | Weekly<sup>e</sup> | Weekly<sup>e</sup> | Weekly<sup>e</sup> | Weekly<sup>e</sup> |
| Self Determination Theory Constructs | TSRQ<sup>f</sup> autonomous self-regulation [51,52] (α=0.81-0.84; correlation with GCOS<sup>g</sup>; r=0.38, P<.001; correlation with HCCQ<sup>h</sup>; r=0.38, P<.001), weight loss attendance (r=0.34, P<.001), body mass index (r=0.11, P<.05), 18-month test-retest autonomous (r=0.47), controlled items (r=0.34) [53], correlation with medication adherence (r=0.58, P<.001) | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| **Exploratory outcomes**           |                                                                    |           |          |         |          |          |           |
| eGFR<sup>i</sup>                   | GFR<sup>j</sup> estimation equations [55,56]                       | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| Ambulatory BP                      | 24-h ambulatory BP with SpaceLabs 90207                           | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| **Methodological parameters**      |                                                                    |           |          |         |          |          |           |
| Recruitment and retention rates: patient/provider satisfaction and usefulness scale (TSUQ<sup>k</sup>) [57] (satisfaction: α=0.96; usefulness: α=0.92; 1-week test-retest r=0.98 [58]) | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| Fidelity checklists: patient level (eg, connection/uploads of Vaica, BP uploads via phone, and opening of messages/education information) and provider level (eg, opening of patient summary reports and phone alerts) | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| Ancillary medication adherence measures | Medication possession rate                                        | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| **Potential moderators/mediators** |                                                                    |           |          |         |          |          |           |
| Demographics                        | Age, education level, income, type of health care insurance        | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| Anthropometrics                     | Height, weight, girth                                              | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| Health literacy                     | Health Literacy Scale [59-62], correlated with short test of functional health literacy in adults. Three questions compared to those in the Short Test of Functional Health Literacy in Adults to detect inadequate health literacy: areas under the receiver operating characteristic curve were 0.76, 0.80, and 0.87. When correlated with Short Form-36 (r=0.86-0.87), it differentiates between healthy status and various types of illnesses (eg, migraine vs healthy using components: physical and mental quality of life; all P<.001) | ✓         | ✓        | ✓       | ✓        | ✓        | ✓         |
| **Adverse events**                  |                                                                    |           |          |         |          |          |           |
Clinic Resting Blood Pressure
BP evaluations will be conducted at enrollment; randomization; and 1, 3, 6, and 12 months. Patients will be seated upright with right arm resting on a table at heart level and a proper cuff size will be fitted. A Dinamap Pro-Care 200 BP device (GE Healthcare, Buckinghamshire, United Kingdom) will be used to take the clinic BP measurements. The Dinamap has been validated following standard auscultatory methods from the British Hypertension Society and the Association for Advancement of Medical Instrumentation [66]. The Dinamap, as well as all other BP devices used in the trial, are calibrated according to the manufacturers’ specifications. A reading will be taken immediately, after 5 minutes of rest, and following a 2-minute interval. The average of the last two readings will be used in the analyses. Subjects in the SMASK group will use the same protocol (ie, a series of 3 BP readings with 5 and 2 minutes in between the first and second readings and between the second and third readings, respectively) at home for BP self-monitoring. This functionality will be embedded within the SMASK app and automatically guide the participants through the protocol with audio guides, timer countdowns, and chimes when each waiting period is complete.

Outcome Measures
Primary Outcome Measures
These include proportion of participants achieving success in meeting and sustaining adherence to the KDIGO guidelines for SBP control (resting SBP <130 mm Hg) and proportion of participants meeting and sustaining monthly medication adherence scores >0.90.

Secondary Outcome Measures
These include provider adherence to KDIGO guidelines, as measured by the appropriateness and timeliness of BP medication changes, and subjects’ self-report of changes in self-determination theory tenants (ie, self-efficacy and autonomous motivation).

Exploratory Outcome Measures
These will include changes in estimated glomerular filtration rate (eGFR) and variability of CNI trough levels (%cv). CNIs have a well-described high inter- and intrapatient variability as well as a narrow therapeutic index. For these reasons, among others, therapeutic drug monitoring of CNI is the standard of care in solid organ transplantation and guides all CNI titrations [67,68]. Changes in the 24-hour ambulatory BP will also be examined.

Participant Timeline
A timeline for participant recruitment, intervention, and follow-up assessments is shown in Figure 1.

Proposed Sample Size
To evaluate SMASK treatment efficacy, 80 patients will be recruited and randomly assigned to either SMASK or SC. The primary outcomes of aim 1 include the proportion of patients with >0.90 medication adherence scores (based on the date/time stamped scores from the electronic trays) and proportion of patients meeting and sustaining adherence the KDIGO guidelines for clinic-based SBP control (<130 mm Hg). In intent-to-treat (ITT) analysis, with 40 patients per group, a two-sided Chi-square test ($\alpha=0.05$) will have >90% power to detect a difference of 35% in proportions of those who are
medication adherent (or meeting and sustaining adherence to the KDIGO BP guidelines) in the SMASK group compared to those in the SC group at the 3-month time point. A difference of 35% in medication adherence between the groups would be considered clinically relevant and warrant changes in clinical practice. Conservative estimates for medication adherence and expected BP control proportions will be used for power calculations. This approach was taken with a small pilot study, and CIs on effect sizes were quite large. Medication adherence observed in the SMASK 3-month feasibility study was 89% (versus 0% in control group; N=19). For the clinic resting BP control, we observed that 90% versus 10% of the participants controlled BP in the SMASK and control groups, respectively. Overall attrition was 10% in the intervention group [69].

Recruitment

Eligible patients were identified from hospital medical records by a research assistant. A research coordinator approached potential subjects in the kidney transplant clinic and obtained voluntary informed consent from patients who were interested in participating. After obtaining informed consent, the clinic resting BP protocol was conducted (see Clinic Resting Blood Pressure) and if SBP ≥130 mm Hg, the subject completed a set of questionnaires (Table 1) and was instructed to wear a SpaceLabs 90207 ambulatory BP monitor (SpaceLabs, Inc., Issaquah, WA) for 24 hours. The subject then began the 1-month screening period, as described above. The study site performs approximately 20 kidney transplants per month. We provide a smartphone and an internet data plan for the SMASK subjects who do not own a smartphone compatible with the SMASK app.

Allocation and Concealment

Subject randomization will be stratified by race and gender and will be conducted by a statistician using a computer-generated random sequence of numbers. Participants who consent to the study and are eligible for randomization at the conclusion of the 1-month medication intake screening period are allocated to either the intervention (SMASK) or SC arm using the computer-generated randomization sequence. Each random sequence is kept concealed in an envelope that is opened by the research coordinator at the time of randomization.

Blinding

The research assistants responsible for assessing primary and secondary outcomes will remain blinded to the patients’ group assignment throughout the study. The physician responsible for making clinical management decisions for those in the SMASK intervention arm will remain blinded to which patients are enrolled in the trial as enhanced attention SC subjects, as they are merely providing SC. However, the participants will not be blinded to their group assignment, as we provide a BP monitor and smartphone as needed to those in the intervention group.

Data Collection and Management

Instruments for data collection are listed in Table 1. Data captured electronically will be transmitted using secure encrypted algorithms and housed on site in a secure HIPAA-compliant relational database.

Statistical Analyses

Primary Outcome Measures

The ITT analysis set will be determined in accordance with the International Conference on Harmonization E9 Guideline “Statistical Principles for Clinical Trials” [70] and will include all randomized subjects. For all subjects included in the ITT analysis set, all available data points will be included in the model. We chose a mixed-effects model approach because this method is a standard method in RCTs and can handle missing data and account for correlated data such as repeated measurements within patients or patients clustered within providers [71-73].

We propose a two-level analysis strategy: Our primary analysis will include the simple mixed-effects model containing the fixed time and intervention group, time, and time-by-intervention as primary independent variables (fixed effects) and MD as a random effect to account for clustering. The main analysis will compare the two intervention groups (SMASK vs SC) at the primary time point outcome at 3 months. We will estimate medication adherence score changes and changes in resting and 24-hour BP for each subject over the trial (preintervention and 1, 3, 6, and 12 months) and the within-subject longitudinal trajectories (eg, slopes) and summarize the mean longitudinal trajectory within each group. Intraclass correlations and variance estimates will be obtained for the efficacy outcomes and covariance structure of the longitudinal scores to determine the sample size (and hence adequate power) for a future effectiveness RCT.

In secondary/exploratory analysis for aim 1 outcomes, the potential influence of a priori specified covariates on these models will be explored, including self-determination theory tenants, demographic and clinical characteristics, and comorbidities. In an additional exploratory analysis, effect modifications of covariates will be examined through inclusion of covariate-by-group interaction terms in the multivariable models.

Secondary Outcome Measures

Secondary outcome measures of changes in self-determination theory tenants (self-efficacy and autonomous self-regulation) and provider adherence to KDIGO guidelines (timing of medication changes) will be investigated using mixed effects models with these outcomes as separate dependent variables, group (SMASK vs SC) as primary independent variable, and the primary outcomes (medication adherence and clinic SBP) and clinical and demographic characteristics as adjustment variables.

Exploratory Outcomes Measures

In exploratory analyses, change in eGFR, variability of calcineurin trough levels, and 24-hour ambulatory BP will be compared between the two groups using pooled t tests (or nonparametric tests, as appropriate). If the end-of study outcomes for eGFR and 24-hour BP are missing, they will be imputed using multiple imputation methods. Further, frequency distributions of adverse events and serious adverse events will
be determined, and proportions for the SMASK versus SC groups will be compared using Chi-square analyses.

**Qualitative Studies**

After the conclusion of the 6-month active trial evaluation, each member of the SMASK group will be approached to participate in a key informant interview of “lived experiences” during the trial. Topic areas with probes will cover expectations, experiences, adherence, motivation, and advice from family and friends. The SMASK lead physician, the transplant nurse coordinator, and other involved staff will be invited to participate in individual interviews to assess the SMASK program from the providers’ point of view. Topics of assessment will include attitudes, barriers and facilitators for use, fidelity, and impact on therapeutic inertia. We will use the constant comparative method of qualitative analysis to code the interviews’ transcript data using NVivo 10.0. Transcripts will be independently reviewed and coded by two reviewers. Once no new themes emerge, thematic saturation will have been reached. We will compare/contrast themes from participants and providers. We will synthesize and integrate the multiple quantitative and qualitative data sources using a triangulation approach. These collective findings will guide further refinements in the SMASK system prior to our efforts to acquire external funding to enable a multisite effectiveness RCT.

**Results**

The SMASK project received funding from NIDDK in June 2016, obtained institutional review board approval in April 2016, and began data collection in July 2016. As of July 2018, we have completed enrollment with a total sample size of 80 participants. Currently, we are analyzing baseline data and upon completion of analysis of the final participant in the 6-month active trial, we will begin analyzing preliminary data to be submitted for peer-review publication.

Approval for important protocol modifications will be sought from the institutional review board. Written informed consent was obtained from all patients before enrollment by a trained research coordinator. There are no anticipated risks associated with participation in the study. Patients are free to withdraw at any time. Data will be kept confidential and anonymized for analyses.

**Discussion**

Despite evidence that medication nonadherence is a major contributor to suboptimal outcomes in kidney transplantation, little progress has been made toward improving medication adherence. To date, research aimed at improving medication adherence in this patient population has been hampered by the use of convenience samples, indirect measures of medication adherence, and ineffective strategies. We aim to address some of these shortcomings in this trial. mHealth technology offers an opportunity to unobtrusively monitor patients, to react in real time to indicators of patient nonadherence, and to tailor the intervention to foster likelihood of sustained adherence to the regimen. Our previous research suggests that the use of an mHealth intervention in this patient population is promising.

This study is novel in both in its design and implementation. To our knowledge, this is the first RCT involving kidney transplant recipients that aimed to evaluate the efficacy of an mHealth medical regimen self-management system (SMASK), which was developed using an iterative design process guided by synergistic tenants from behavioral and technology application theories and direct guidance from kidney transplant recipients, transplant physicians, and associated health care team members. Importantly, the SMASK program utilizes timely regimen reminder tactics with immediate feedback of the results to the patient and real-time relay of patients’ regimen engagement to a HIPPA-compliant server. This allows for the use of automated, patient-tailored, motivational, and social reinforcement messages framed upon their degree of adherence. Importantly, the health care provider is intimately involved via weekly tailored emailed subject summary reports that allow more timely medical management decisions aimed at improved medication adherence, earlier BP control, and avoidance of unnecessary escalation of care. Collectively, these strategies are directed at enhancing patients’ self-efficacy to perform the medical regimen behaviors and improving the levels of autonomous, self-directed motivation to sustain these behaviors across time with the ultimate aim of improving long-term graft survival.

There are several limitations to this study that need to be addressed. First, although the study recruits from a single transplant center, limiting its generalizability, the center is the sole transplant provider for the state of South Carolina and has a catchment population of over 4.6 million persons that encompass a wide range of ethnic, educational, and socioeconomic backgrounds. Second, while it cannot be assumed that the subjects’ willingness to use the SMASK system can be divorced entirely from the appeal of the financial compensation, we targeted the compensation at a level that would only cover the inconvenience and cost of otherwise unnecessary travel and time spent waiting. Finally, while the current study duration of only 12 months is long enough to demonstrate improvements in medication adherence and BP control, it will not be long enough to demonstrate significant improvements in graft function or graft survival. However, these outcomes will be the focus of subsequent longitudinal studies, and participants in this study will be asked to continue providing relevant data to assess longer-term outcomes.

In conclusion, this study will provide important and novel data regarding the efficacy of the mHealth SMASK system to improve medication adherence and BP control in a medication-nonadherent cohort of uncontrolled hypertensive kidney transplant recipients. An efficacious SMASK intervention would lead to a larger, multicenter, effectiveness RCT powered to evaluate clinical events in a real-world setting and with the potential to demonstrate improved outcomes at lower cost than the standard of care.
Acknowledgments

The study was funded by the National Institute of Health-National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK103839). The study sponsor and funders will play no active role in study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit reports for publication and will have no ultimate authority over any of these activities.

Authors’ Contributions

JM, FT, LN, MM, and PB conceived the study. JM, JC, LS, and FT drafted the manuscript. JM, FT, LN, MM, and JC critically reviewed the manuscript. All authors read and approved the final submission.

Conflicts of Interest

None declared.

Multimedia Appendix 1

National Institutes of Health (NIH) peer-review reports.

References

1. United States Renal Data System. 2017 Jul 23. USRDS 2017 Annual Data Report URL: https://www.usrds.org/adr.htm [accessed 2019-06-03] [WebCite Cache ID 78rJBl5hQ6]
2. OPTN. Organ Procurement and Transplant Network. 2018 Jul 23. URL: http://optn.transplant.hrsa.gov/ [accessed 2019-06-03] [WebCite Cache ID 78rJDuwQt]
3. Manninen DL, Evans RW, Dugan MK. Work disability, functional limitations, and the health status of kidney transplantation recipients posttransplant. Clin Transpl 1991:193-203. [Medline: 1820116]
4. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996 Jul;50(1):235-242 [FREE Full text] [Medline: 8807593]
5. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettinger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999 Dec 02;341(23):1725-1730. [doi: 10.1056/NEJM199912023412303] [Medline: 10580071]
6. Neipp M, Karavul B, Jacobs S, Meyer zu Vilsendorf A, Richter N, Becker T, et al. Quality of life in adult transplant recipients more than 15 years after kidney transplantation. Transplantation 2006 Jun 27;81(12):1640-1644. [doi: 10.1097/01.tp.0000226070.74443.fb] [Medline: 16794528]
7. Lamb K, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011 Mar;11(3):450-462 [FREE Full text] [doi: 10.1111/j.1600-6143.2010.03283.x] [Medline: 20973913]
8. Thomas B, Taber DJ, Srinivas TR. Hypertension after kidney transplantation: a pathophysiologic approach. Curr Hypertens Rep 2013 Oct;15(5):458-469. [doi: 10.1007/s11906-013-0381-0] [Medline: 23923793]
9. Palanisamy A, Schiltz CE, Pilch NA, Hunt KJ, Nadig SN, Dowden JE, et al. Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: a retrospective analysis. Blood Press 2015 Feb;24(1):14-22. [doi: 10.3109/08037051.2014.934527] [Medline: 25048253]
10. Małyszko J, Małyszko J, Bachórzewska-Gajewska H, Poniatowski B, Dobrzynski S, Myśliwiec M. Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications. Transplant Proc 2009 Oct;41(8):3069-3072. [doi: 10.1016/j.transproceed.2009.07.078] [Medline: 19857679]
11. Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int 2011 Jun;24(6):523-533 [FREE Full text] [doi: 10.1111/j.1432-2277.2011.01242.x] [Medline: 21382101]
12. Paoletti E, Gherzi M, Amidone M, Massarino F, Cannella G. Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 2009 Jun 27;87(12):1864-1869. [doi: 10.1097/TP.0b013e3181746775] [Medline: 19543066]
13. Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis 2011 Feb;57(2):331-341. [doi: 10.1053/j.ajkd.2010.10.048] [Medline: 21251543]
14. De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995 Feb 15;59(3):340-347. [Medline: 7871562]
15. Denhaerynck K, Dobbels F, Cleemput I, Desmyttere A, Schäfer-Keller P, Schaub S, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int 2005 Oct;18(10):1121-1133 [FREE Full text] [doi: 10.1011/j.1432-2277.2005.00176.x] [Medline: 16162098]
16. Nevins T, Kruse L, Skeans MA, Thomas W. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001 Oct;60(4):1565-1570 [FREE Full text] [doi: 10.1046/j.1523-1755.2001.00961.x] [Medline: 11576374]

17. Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004 Sep;4(9):1509-1513 [FREE Full text] [doi: 10.1111/j.1600-6143.2004.00537.x] [Medline: 15307839]

18. Takemoto S, Pinsky BW, Schnitzler MA, Lentine KL, Willoughby LM, Burroughs TE, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007 Dec;7(12):2704-2711 [FREE Full text] [doi: 10.1111/j.1600-6143.2007.01966.x] [Medline: 17868065]

19. Dew M, DiMartini AF, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation 2007 Apr 15;83(7):858-873. [doi: 10.1097/TP.0b013e3180258599.65257.a6] [Medline: 17460556]

20. Nerini E, Bruno F, Citterio F, Schena FP. Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help? J Nephrol 2016 Oct;29(5):627-636. [doi: 10.1007/s40620-016-0273-x] [Medline: 26885659]

21. Weng F, Chandwani S, Kurtyka KM, Zacker C, Chisholm-Burns MA, Demissie K. Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant: a cross-sectional study. BMC Nephrol 2013 Dec 01;14:261 [FREE Full text] [doi: 10.1186/1471-2369-14-261] [Medline: 24289809]

22. Griva K, Davenport A, Harrison M, Newman SP. Non-adherence to immunosuppressive medications in kidney transplantation: intent vs. forgetfulness and clinical markers of medication intake. Ann Behav Med 2012 Aug;44(1):85-93. [doi: 10.1007/s12160-012-9359-4] [Medline: 22454221]

23. McGillicuddy J, Weiland AK, Frenzel RM, Mueller M, Brunner-Jackson BM, Taber DJ, et al. Patient attitudes toward mobile phone-based health monitoring: questionnaire study among kidney transplant recipients. J Med Internet Res 2013 Jan 08;15(1):e6 [FREE Full text] [doi: 10.2196/jmir.2284] [Medline: 23305649]

24. Browning R, McGillicuddy JW, Treiber FA, Taber DJ. Kidney transplant recipients' attitudes about using mobile health technology for managing and monitoring medication therapy. J Am Pharm Assoc (2003) 2016;56(4):450-454.e1 [FREE Full text] [doi: 10.1016/j.japh.2016.03.017] [Medline: 27450140]

25. McGillicuddy J, Gregoski MJ, Weiland AK, Rock RA, Brunner-Jackson BM, Patel SK, et al. Mobile Health Medication Adherence and Blood Pressure Control in Renal Transplant Recipients: A Proof-of-Concept Randomized Controlled Trial. JMIR Res Protoc 2013 Sep 04;2(2):e32 [FREE Full text] [doi: 10.2196/resprot.2633] [Medline: 24004517]

26. McGillicuddy J, Taber DJ, Mueller M, Patel S, Baliga PK, Chavin KD, et al. Sustainability of improvements in medication adherence through a mobile health intervention. Prol Transplant 2015 Sep;25(3):217-223. [doi: 10.7182/pitr2015975] [Medline: 26308780]

27. Duncan S, Annunziato RA, Dunphy C, LaPointe Rudow D, Shneider BL, Shemesh E. A systematic review of immunosuppressant adherence interventions in transplant recipients: Decoding the streetlight effect. Pediatr Transplant 2018 Dec;22(1) [FREE Full text] [doi: 10.1111/petr.13086] [Medline: 29218760]

28. Cukor D, Ver Halen N, Pencille M, Tedla F, Salifu M. A Pilot Randomized Controlled Trial to Promote Immunosuppression Adherence Among Kidney Transplant Recipients. Nephron 2017;135(1):6-14 [FREE Full text] [doi: 10.1159/000448627] [Medline: 28049201]

29. De Geest S, Schäfer-Keller P, Denhaerynck K, Thannberger N, Köfer S, Bock A, et al. Supporting medication adherence in renal transplantation (SMART): a pilot RCT to improve adherence to immunosuppressive regimens. Clin Transplant 2006;20(3):359-368. [doi: 10.1111/j.1399-0012.2006.00493.x] [Medline: 16824155]

30. Breu-Dejean N, Driot D, Dupouy J, Lapeyre-Mestre M, Rostaing L. Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients: 10-Year Results of a Prospective Randomized Study. Exp Clin Transplant 2016 Feb;14(1):38-44 [FREE Full text] [Medline: 26862823]

31. Joost R, Dörje F, Schwitulla J, Eckardt KU, Hugo C. Intensified pharmaceutical care is improving immunosuppressive medication adherence in kidney transplant recipients during the first post-transplant year: a quasi-experimental study. Nephrol Dial Transplant 2014 Aug;29(8):1597-1607. [doi: 10.1093/ndt/gfu207] [Medline: 24914089]

32. Chisholm M, Vollenweider LJ, Mullow LL, Jagadeesan M, Wynn JJ, Rogers HE, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000 Oct 27;70(8):1240-1244. [Medline: 11063348]

33. Reese P, Bloom RD, Trofe-Clark J, Mussell A, Leidy D, Levsky S, et al. Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial. Am J Kidney Dis 2017 Mar;69(3):400-409. [doi: 10.1053/j.ajkd.2016.10.017] [Medline: 27940063]

34. Hardstaff R, Green K, Talbot D. Measurement of compliance posttransplantation—the results of a 12-month study using electronic monitoring. Transplant Proc 2003 Mar;35(2):796-797. [Medline: 12644142]

35. Henriksson J, Tydén G, Höijer J, Wadström J. A Prospective Randomized Trial on the Effect of Using an Electronic Monitoring Drug Dispensing Device to Improve Adherence and Compliance. Transplantation 2016 Jan;100(1):203-209. [doi: 10.1097/TP.0000000000000971] [Medline: 26588006]

36. Taber D, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation 2017 Dec;101(12):2931-2938 [FREE Full text] [doi: 10.1097/TP.0000000000001840] [Medline: 28658199]
37. Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LPC, Weimar W, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transplant Int 2016 Nov;29(11):1158-1167 [FREE Full text] [doi: 10.1111/tri.12798] [Medline: 27188932]

38. Borra L, Roodnat JI, Kal JA, Mathot RAA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010 Aug;25(8):2757-2763. [doi: 10.1093/ndt/gfq96] [Medline: 20190242]

39. O'Regan J, Canney M, Connaughton DM, O'Kelly P, Williams Y, Collier G, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol 2016 Apr;29(2):269-276. [doi: 10.1007/s40620-015-0230-0] [Medline: 26374111]

40. Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim SJ, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012 Dec;34(6):680-685. [doi: 10.1097/FTD.0b013e3182731809] [Medline: 23149441]

41. Levesque C, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ. Validating the theoretical structure of the Treatment Self-Regulation Questionnaire across three different health behaviors. Health Educ Res 2007 Aug;22(5):691-702. [doi: 10.1093/her/cyl148] [Medline: 17138613]

42. Ryan R, Connell JP. Perceived locus of causality and internalization: examining reasons for acting in two domains. J Pers Soc Psychol 1989 Nov;57(5):749-761. [Medline: 2810024]

43. Williams G, Grow VM, Freedman ZR, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol 1996 Jan;70(1):115-126. [Medline: 8558405]

44. Williams G, Rodin GC, Ryan RM, Grolnick WS, Deci EL. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychol 1998 May;17(3):269-276. [Medline: 9619477]

45. Poggio E, Wang X, Weinstein DM, Issa N, Dennis VW, Braun WE, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006 Jun;5(6):1306-1311 [FREE Full text] [doi: 10.1111/j.1660-6413.2005.00861.x] [Medline: 15888034]

46. Poggio E, Wang X, Weinstein DM, Issa N, Dennis VW, Braun WE, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006 Jun;5(6):1306-1311 [FREE Full text] [doi: 10.1111/j.1660-6413.2005.00861.x] [Medline: 15888034]

47. Bakken S, Guillon-Figueroa L, Izquierdo R, Lee NJ, Morin P, Palmas W, IDEATel Consortium. Development, validation, and use of English and Spanish versions of the telemedicine satisfaction and usefulness questionnaire. J Am Med Inform Assoc 2006;13(6):660-667 [FREE Full text] [doi: 10.1197/jamia.M2146] [Medline: 16929036]

48. Demiris G, Speedie S, Finkelstein S. A questionnaire for the assessment of patients' impressions of the risks and benefits of home telecare. J Telemed Telecare 2000;6(5):278-284. [doi: 10.1258/1357633001935914] [Medline: 11070589]

49. Williams M, Baker DW, Parker RM, Nursrs JR. Relationship of functional health literacy to patients' knowledge of their chronic disease. A study of patients with hypertension and diabetes. Arch Intern Med 1998 Jan 26;158(2):166-172. [Medline: 9448555]
60. Chew L, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med 2004 Sep;36(8):588-594 [FREE Full text] [Medline: 15343421]

61. Sarkar U, Schilling D, López A, Sudore R. Validation of self-reported health literacy questions among diverse English and Spanish-speaking populations. J Gen Intern Med 2011 Mar;26(3):265-271 [FREE Full text] [doi: 10.1007/s11606-010-1552-1] [Medline: 21057882]

62. Chew L, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med 2008 May;23(5):561-566 [FREE Full text] [doi: 10.1007/s11606-008-0520-5] [Medline: 18335281]

63. Cohen S, Tyrrell DA, Smith AP. Negative life events, perceived stress, negative affect, and susceptibility to the common cold. J Pers Soc Psychol 1993 Jan;64(1):131-140. [Medline: 8421249]

64. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983 Dec;24(4):385-396. [Medline: 6688147]

65. Sanne S, Muntner P, Kawasaki L, Hyre A, DeSalvo KB. Hypertension knowledge among patients from an urban clinic. Ethn Dis 2008;18(1):42-47. [Medline: 18447098]

66. Reinders A, Reggiori F, Shennan AH. Validation of the DINAMAP ProCare blood pressure device according to the international protocol in an adult population. Blood Press Monit 2006 Oct;11(5):293-296. [doi: 10.1097/01.mbp.0000217998.96967.fb] [Medline: 16932038]

67. Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus - Pharmacokinetic Considerations for Clinicians. Curr Drug Metab 2018;19(4):342-350. [doi: 10.2174/1389200219666180101104159] [Medline: 29298646]

68. Staatz C, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43(10):623-653. [doi: 10.2165/00003088-200443100-00001] [Medline: 15244955]

69. McGillicuddy JW, Gregoski MJ, Brunner-Jackson BM, Weiland AK, Patel SK, Rock RA, et al. Facilitating medication adherence and eliminating therapeutic inertia using wireless technology: proof of concept findings with uncontrolled hypertensives and kidney transplant recipients. In: Journal of the Association for Computer Machinery. New York, NY: ACM; 2012 Presented at: WH ‘12 Proceedings of the conference on Wireless Health, Article No. 12; October 23 - 25, 2012; San Diego, California p. 1-9. [doi: 10.1145/2448096.2448108]

70. Phillips A, Haudiquet V. ICH E9 guideline 'Statistical principles for clinical trials': a case study. Stat Med 2003 Jan 15;22(1):1-11; discussion 13. [doi: 10.1002/sim.1328] [Medline: 12486747]

71. Gibbons R, Hedeker D. Longitudinal Data Analysis. Hoboken, NJ: John Wiley & Sons, Inc; 2006.

72. O'Kelly M, Ratitch B. Clinical trials with missing data: a guide for practitioners. In: Statistics in practice. Hoboken, NJ: Wiley; 2014.

73. McCulloch CE, Searle SR, Neuhaus JM. Generalized, Linear, and Mixed Models. Hoboken, NJ: Wiley-Interscience; 2001.

Abbreviations

  CNI: calcineurin inhibitor
  cv: coefficient of variation
  eGFR: estimated glomerular filtration rate
  ESRD: end-stage renal disease
  HIPAA: Health Insurance Portability and Accountability Act
  ITT: intent to treat
  KDIGO: Kidney Disease Improving Global Outcomes
  mHealth: mobile health
  MUSC: Medical University of South Carolina
  NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
  SBP: systolic blood pressure
  SC: standard care
  SMASK: Smartphone Medication Adherence Saves Kidneys
